CryoXtract Instruments Introduces the New CXT 353 Frozen Sample Aliquotter
October 29 2015 - 2:00AM
Business Wire
- This second generation benchtop model
features faster cycle times, an increased range of sample volumes
and a smaller probe size that allows for more precise sample
acquisition.
- This new product will be showcased at
CryoXtract’s booth #101 at the Association for Molecular Pathology
(AMP) 2015 Annual Meeting in Austin, Texas (November 5th –
7th).
CryoXtract Instruments LLC, a provider of automated frozen
aliquotting systems for high-value frozen biosamples, is pleased to
introduce the CXT 353 Frozen Sample Aliquotter, the next generation
semi-automated benchtop instrument for frozen aliquotting of a wide
range of sample types including tissue, feces, plasma, whole blood,
urine and other biofluids.
The CXT 353 features a compact benchtop design, user-friendly
touch screen operation and compatibility with a wide range of vial
types. The CXT 353 expands upon the company’s original CXT 350
solution with faster cycle times and actuated ejection, enhancing
cold chain sample processing and increasing precision in core
deposition.
“This is a welcome expansion to our product line that will
especially meet the needs of researchers working with labile
molecules,” said Graham Long, Vice President of Business
Development and Marketing. “This new model allows greater
flexibility to support a wider variety of research needs. We are
excited to introduce customers to the enhanced functionality of the
benchtop CXT 353.”
Other features of the CXT 353 include a removable guard for
simplified cleaning, increased range of aliquot volumes (now
10-250μL) and a new 1.5 mm single-use coring probe that enables
smaller core volumes for targeted tissue acquisition. As with the
CXT 350, single-use probes in the CXT 353 prevent sample-to-sample
carryover and contamination and the instrument’s laser-targeting
feature enables coring of specific tissue sample regions,
streamlining tissue processing within pathology workflows.
“The CXT 353 platform was developed in response to the needs of
our customers and is a manifestation of our commitment to designing
the best products on the market,” said CryoXtract Instruments Chief
Executive Officer Dan Espinal.
The CXT 353 joins the company’s portfolio of bioanalytical
solutions that also include the CXT 750 Automated Frozen Sample
Aliquotter. The United States Patent Office (USPTO) recently
granted to CryoXtract Instruments its first patent for the CXT 750,
validating the assistance it offers with bioanalysis in drug
discovery and development.
The new patent addresses the CXT 750’s ability to more
accurately acquire specific, user-defined volumes from frozen
samples. This unique functionality is particularly relevant to the
bioanalysis of drug molecules for drug metabolism and
pharmacokinetics and supports the effective use of frozen samples
without exposing them to unnecessary, damaging freeze/thaw
cycles.
CryoXtract Instruments’ solutions enable the automated
extraction of multiple frozen cores from a single frozen sample
while maintaining the parent and extracted samples at temperatures
below -80°C. The ability to extract frozen aliquots while
preserving the parent sample prevents degradation due to thawing
and maximizes the use of critical samples such as rare disease,
late-stage disease and pediatric samples. Frozen aliquotting helps
to stabilize labile small molecule compounds, peptides and proteins
for bioanalysis and preserves sample quality for additional testing
or re-analysis.
CryoXtract Instruments will exhibit at the annual meeting of the
Association for Molecular Pathology (AMP) in Austin, Texas from
November 5th – 7th. The company will be showcasing its CXT 353
Frozen Sample Aliquotter at booth #101.
To learn more about the AMP conference,
visithttp://www.amp.org/meetings/2015/
For more information on CryoXtract Instruments,
visitwww.cryoxtract.com
About CryoXtract Instruments, LLCCryoXtract develops and
commercializes automation solutions that allow for the retrieval of
multiple frozen samples from a single frozen biospecimen without
exposing the source to the deleterious biological impact from
freeze/thaw cycling. The company's automation technology system
improves frozen biosample processing, protects the viability of
frozen biosamples after cores have been extracted, improves lab
efficiencies and economics, and helps optimize scientific outcomes.
CryoXtract is a subsidiary of Boston-based Allied Minds, Inc. For
more information, please visit www.cryoxtract.com.
About Allied MindsAllied Minds (LSE: ALM) is an
innovative U.S. science and technology development and
commercialization company. Operating since 2006, Allied Minds
forms, funds, manages and builds products and businesses based on
innovative technologies developed at leading U.S. universities and
federal research institutions. Allied Minds serves as a diversified
holding company that supports its businesses and product
development with capital, central management and shared services.
More information about the Boston-based company can be found
at www.alliedminds.com.
Allied Minds Forward-Looking StatementThis press release
contains statements that are or may be forward-looking statements,
including statements that relate to the company’s future prospects,
developments and strategies. The forward-looking statements are
based on current expectations and are subject to known and unknown
risks and uncertainties that could cause actual results,
performance and achievements to differ materially from current
expectations, including, but not limited to, those risks and
uncertainties described in the risk factors included in the
company’s regulatory filings. These forward-looking statements are
based on assumptions regarding the present and future business
strategies of the company and the environment in which it will
operate in the future. Each forward-looking statement speaks only
as at the date of this press release. Except as required by law,
regulatory requirement, the Listing Rules and the Disclosure and
Transparency Rules, neither the company nor any other party intends
to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151028006870/en/
ArcPoint Strategic CommunicationsJoan DeCoste,
617-484-1660jdecoste@arcpointstrategy.com
Allied Minds (LSE:ALM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allied Minds (LSE:ALM)
Historical Stock Chart
From Apr 2023 to Apr 2024